(12) United States Patent
`Paton et al.
`
`(10) Patent N0.2
`(45) Date of Patent:
`
`US 7,892,549 B2
`*Feb. 22, 2011
`
`US007892549B2
`
`(54) TREATMENT WITH ANTI-ERBB2
`ANTIBODIES
`
`(75) Inventors: Virginia E. Paton, Oakland, CA (US);
`Steven Shak, Burlingame, CA (Us);
`Susan D. Hellmann, San Carlos, CA
`(US)
`(73) Assignee: ginengech, Inc., South San Francisco,
`(U )
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 1827 days.
`
`( * ) Notice:
`
`This patent is subject to a terminal dis-
`Clalmer-
`
`(21) Appl' NO‘: 10656324
`
`(22) Filed;
`
`Feb 3, 2003
`
`(65)
`
`Prior Publication Data
`Us 2004/0037823 A9
`Feb. 26, 2004
`
`Related US. Application Data
`
`(63) Continuation of application No. 09/208,649, ?led on
`Dec' 10 1998'
`_
`_
`_ _’
`(60) Prov1s1onal appl1cat1on No. 60/069,346, ?led on Dec.
`12, 1997.
`
`51
`Int. Cl.
`(2006.01)
`(
`) A61K 39/395
`(2006.01)
`C07K 16/28
`(2006.01)
`C07K 16/30
`(52) us. Cl. ............ .. 424/143.1, 424/1301, 424/1331,
`424/134.1; 424/135.1; 424/136.1; 424/138.1;
`424/141.1; 424/152.1; 424/155.1; 424/156.1;
`424/172.1; 424/174.1
`(58) Field of Classi?cation Search ............ .. 424/1301,
`424/133.1,138.1,141.1,143.1,155.1,174.1,
`424/134.1,135.1,1361,152.1,1561,172.1
`See application ?le for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`4/1977 Davies
`4,017,471 A
`6/1988 Frankel et a1.
`4,753,894 A
`6/1990 Bargmann et a1.
`4,935,341 A
`7/1990 Mendelsohn et a1.
`4,943,533 A
`4,968,603 A 11/1990 Slamon etal.
`4,975,278 A 12/1990 Senter et a1.
`4,994,558 A
`2/1991 Armour et a1.
`5,169,774 A 12/1992 Frankel et a1.
`5,183,884 A
`2/1993 Kraus etal.
`5,288,477 A
`2/1994 Bacus
`5,359,046 A 10/1994 Capon et a1.
`5,367,060 A 11/1994 Vandlen et a1.
`5,401,638 A
`3/1995 Carneyetal.
`5,464,751 A 11/1995 Greene et a1.
`5,480,968 A
`1/1996 Kraus et a1.
`5,514,554 A
`5/1996 Bacus
`5,571,894 A 11/1996 Wels etal.
`
`5,578,482 A 11/1996 Lippman et a1.
`5,587,458 A 12/1996 King et a1.
`5,604,107 A
`2/1997 Carne et a1.
`5,641,869 A
`@997 vandlzn et 31‘
`5,663,144 A
`9/1997 Greene et 31.
`5,677,171 A “M997 Hudziak et al‘
`5,705,157 A
`1/1998 Greene
`i
`5,725,856 A
`5,726,023 A
`5,728,687 A
`5,747,261 A
`5,770,195 A
`5,772,997 A
`5,776,427 A
`
`it :1:
`3/1998 HudZiak et a1.
`3/1998 Cheever et al'
`3/1998 Bissery
`5/1998 King et :11.
`6/1998 HudZiak et al.
`6/1998 Hudziak et a1‘
`7/1998 Thorpe etal.
`
`7/1998 Arakawa et a1.
`5,783,186 A
`7/1998 Koski
`5,783,404 A
`9/1998 Cheever et a1.
`5,801,005 A
`9/1998 Plowman
`5,804,396 A
`5,821,337 A 10/1998 Carter et a1.
`5,824,311 A 10/1998 Greene etal
`5,834,229 A 11/1998 Vandlen et 31.
`5,837,243 A 11/1998 Deo et a1.
`
`5’837’523 A “H998 Greene et 31'
`5,840,525 A 11/1998 Vandlen et a1.
`5,846,538 A 12/1998 Cheever et a1.
`
`-
`(Commued)
`FOREIGN PATENT DOCUMENTS
`
`EP
`
`0599274 A1
`
`6/1994
`
`.
`(Commued)
`OTHER PUBLICATIONS
`
`Kim,
`
`et 31, 1119 1 Cancer, 1021 428-434, 2002*
`
`(Continued)
`Primary ExamineriAlana M. Harris
`Assistant ExamineriAnne L Holleran
`(74) Attorney, Agent, or F irmiAmold & Porter LLP; Diane
`Marschang; Ginger R. Dreger
`
`(57)
`
`ABSTRACT
`
`The present invention concerns the treatment of disorders
`characterized by the overexpression of ErbB2. More speci?
`cally, the invention concerns the treatment of human patients
`susceptible to or diagnosed With cancer overexpressing
`ErbB2 With a combination of an anti-ErbB2 antibody and a
`chemotherapeutic agent other than an anthracycline, e.g.
`doxorubicin or epirubicin.
`
`17 Claims, 1 Drawing Sheet
`
`BIOEPIS EX. 1001
`Page 1
`
`

`

`US. PATENT DOCUMENTS
`
`5,846,749 A 12/1998 51991011 eta1~
`5,856,089 A
`V1999 Wang etal-
`5,856,110 A
`V1999 Vandlen er 91-
`5,859,206 A
`1/1999 Vandlen eta1~
`5,869,445 A
`2/1999 Cheeveretal
`5,876,712 A
`3/1999 CheeVeretaL
`5,877,305 A
`3/1999 Huston eta1~
`5,908,835 A
`6/1999 Bissery
`5,910,486 A
`6/1999 Curiel e191
`5,922,845 A
`7/1999 D90 eta1~
`5,925,519 A
`7/1999 Jensen eta1~
`5939531 A
`8/1999 W918 eta1~
`5977322 A 11/1999 Marksetal
`5,985,553 A 11/1999 King eta1~
`5994071 A 11/1999 ROSS 9M1
`6,015,567 A
`1/2000 Huclzlaketd
`6,028,059 A
`2/2000 Cunel er 91-
`6,054,297 A
`4/2000 Carter et a1.
`6,054,561 A
`4/2000 Ring
`6,123,939 A
`9/2000 Shawver et a1.
`6,165,464 A 12/2000 Hudziaketal.
`6,214,388 B1
`4/2001 Benz et a1.
`6,214,863 B1
`4/2001 Bissery
`6,267,958 B1
`7/2001 Andyaetal.
`6,270,765 B1
`8/2001 Deo et a1.
`6,316,462 B1
`11/2001 Bishop et a1.
`6,333,348 B1
`12/2001 Vogelet a1.
`6,339,142 B1
`1/2002 Basey et 31.
`6,387,371 B1
`5/2002 Hudziaketal.
`6,395,272 B1
`5/2002 Deo et a1.
`6,395,712 B1
`5/2002 Hung et a1.
`6,399,063 B1
`6/2002 Hudziak et a1.
`6,407,213 B1
`6/2002 Carter 61 a1.
`
`1/2003 Margietal. 1
`6,512,097 B1
`92003 Bau man eta.
`6,627,196 B1
`iii/20in 6min.
`6,639,055 Bi
`2/2004 Andya et a1.
`6,685,940 B2
`4/2004 Carter et a1.
`6,719,971 B1
`10/2004 Caner et a1.
`6,800,738 B1
`11/2004 Clelandetal.
`6,821,515 B1
`5/2006 Sliwkowski
`7,041,292 B1
`6/2006 Andya et a1.
`7,060,268 B2
`8/2006 Erickson et a1.
`7,097,840 B2
`8/2001 Andya et a1.
`2001/0014326 A1
`1/2002 Erickson et a1.
`2002/0001587 A1
`6/2002 Buchsbaum
`2002/0076408 A1
`2002/0155527 A1 10/2002 Stuart et a1.
`2003/0103973 A1
`6/2003 Rockwell etal.
`2003/0108545 A1
`6/2003 Rockwell etal.
`2003/0147884 A1
`8/2003 Paton et a1.
`2003/0170234 A1
`9/2003 Hellmann
`
`1/2004 Blssery
`2004/0013660 A1
`2/2004 Paton et a1.
`2004/0037823 A9
`2/2004 Baughman et a1.
`2004/0037824 A1
`6/2004 Bossenmaier et 31.
`2004/0106161 A1
`2004/0236078 A1 11/2004 Carter et a1.
`2004/0258685 A1 12/2004 Brunetta et a1.
`2005/0002928 A1
`1/2005 Hellmann
`2005/0208043 A1
`9/2005 Adams et a1.
`2005/0238640 A1 10/2005 Sliwkowski
`2005/0244417 A1 11/2005 Ashkenazi et a1.
`2006/0013819 A1
`1/2006 Kelsey
`2006/0018899 A1
`1/2006 Kao et a1.
`2006/0034840 A1
`2/2006 Agus
`2006/0034842 A1
`2/2006 Adams et a1.
`2006/0073143 A1
`4/2006 Adams et a1.
`2006/0083739 A1
`4/2006 Sliwkowski
`2006/0088523 A1
`4/2006 Andya et a1.
`2006/0099201 A1
`5/2006 Andya et a1.
`
`US 7,892,549 B2
`Page 2
`
`6/2006 Amler et a1.
`2006/0121044 A1
`7/2006 Allison etal.
`2006/0165702 A1
`8/2006 Deryncketal.
`2006/0188509 A1
`8/2006 Adams et a1.
`2006/0193854 A1
`9/2006 Adams et a1.
`2006/0198843 A1
`9/2006 Sliwkowskietal.
`2006/0204505 A1
`9/2006 Baughman etal.
`2006/0210561 A1
`2006/0228745 A1 10/2006 Mass
`2006/0275305 A1 12/2006 Bryant
`2006/0275306 A1 12/2006 Andyaetal.
`2007/0020261 A1
`1/2007 Sliwkowskietal.
`2007/0026001 A1
`2/2007 Ashkenazietal.
`2007/0037228 A1
`2/2007 Moecks et a1.
`2007/0166753 A1
`7/2007 Mass
`2007/0184055 A1
`8/2007 Sliwkowski
`2007/0202516 A1
`8/2007 Mass
`2007/0224203 A1
`9/2007 Friess et a1.
`2007/0269429 A1 11/2007 Kelseyetal.
`2007/0292419 A1 12/2007 Hellmann
`
`EP
`EP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`JP
`W0
`W0
`
`W0
`$3
`W0
`
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`W0
`W0
`
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`W0
`
`FOREIGN PATENT DOCUMENTS
`616812 A1
`9/1994
`0711565 B1
`g/199g
`3.240498
`10/1991
`5.117165
`5/1993
`5.170667
`7/1993
`5.213775
`g/1993
`5.317084
`12/1993
`95006982 B2
`1/1995
`7.59588
`3/1995
`2761543 B2
`6/199g
`2895105 B2
`5/1999
`W0 37/076216
`12/19g7
`WO 89/06692
`'7/l989
`
`Wow/02062
`$33833;
`WO93/03741
`
`WO 93/1222‘)
`WO 93/16185
`WO 93/2132
`WO 93/21319
`WO 94/00136
`W0 94/22478
`WO 94/28127
`W0 95/16051
`W0 95/17507
`W0 95/2g4g5
`WO 96/07321
`WO 96/1667}
`W0 96/l8409
`
`WO 97/00271
`WO 97/20858
`
`2,1991
`3133;
`3/1993
`
`6/1993
`8/1993
`10/1993
`10/1993
`l/1994
`10/1994
`12/1994
`6/1995
`6/1995
`10/1995
`3/1996
`6/1996
`6/l996
`
`1,1997
`6,1997
`
`8/1997
`WO 97/27848
`10/1997
`W0 97/38731
`V1998
`WO 98/02463
`4/1998
`WO 98/17797
`5/1998
`WO 98/18489
`8/1998
`WO 98/33914
`10/1998
`WO 98/45479
`5/1999
`W0 99/24401
`5/1999
`W0 99/25320
`6/1999
`W0 99/31140
`10/2000
`W0 00/61145
`10/2000
`W0 00/61185
`W0 00/69460 A1 11/2000
`W0 01/87334
`11/2001
`W0 02/055106
`7/2002
`
`BIOEPIS EX. 1001
`Page 2
`
`

`

`US 7,892,549 B2
`Page 3
`
`W0 WO 2007/145862 A2 12/2007
`
`OTHER PUBLICATIONS
`
`Nabholtz, J .M., et al, Breast Cancer Research and Treatment, 64(1):
`p. 82, #327, 2000*
`Nabholtz, J. M., et al., European Journal of Cancer, 37(suppl. 6):
`S190, #695, 2001 .*
`Perez et al., Seminars in Oncology, 23(5, suppl 11): 41-45, Oct.
`1996*
`van Oosterom et al., “Docetaxel (Taxotere), a review of preclinical
`and clinical experience. Part II: Clinical experience” Anti-Cancer
`Drugs (Abstract only) 6(3):356-368 (Jun. 1995).
`Albanell et al., “Trastuzumab, a humanized anti-HER2 monoclonal
`antibody, for the treatment of breast cancer” Drugs of Today
`35(12):931-946 (1999).
`Drug
`Complete
`MartindaleiT he
`“Amino glutethimide”
`ReferenceiMonographs (website version of product information)
`pp. 1-4 (2003).
`Argiris and DiGiovanna, “Synergistic interactions between
`tamoxifen and HERCEPTIN TM” Proceedings of the American
`Association for Cancer Research (Abstract #4565) 41:718 (Mar.
`2000).
`“Arimidex (anastrozole) Tablets” Physicians’ Desk Reference
`(website version of product information) pp. 1-14 (2003).
`“Aromasin (exemestane tablets)” Physicians’ Desk Reference
`(website version of product information) pp. 1-9 (2003).
`Benz et al., “Estrogen-dependent, tamoxifen-resistant tumorigenic
`growth of MCF-7 cells transfected with HER2/neu” Breast Cancer
`Research & Treatment 24(2):85-95 (1992).
`Brueggemeier, R., “Aromatase, aromatase inhibitors, and breast can
`cer” American Journal of Therapeutics 8(5):333-344 (Sep.-Oct.
`2001).
`“A concerted attack on cancer” Scrip Magazine 2617(Review Issue
`2000):68-70 (Feb. 14, 2001).
`Dati et al., “Inhibition of c-erbB-2 oncogene expression by estrogens
`in human breast cancer cells” Oncogene 5(7): 1001-1006 (Jul. 1990).
`“Femara (letrozole tablets)” Physicians’ Desk Reference (website
`version of product information) pp. 1-13 (2003).
`Grem et al., “A phase II evaluation of combination chemotherapy
`plus amino glutethimide in women with metastatic or recurrent breast
`carcinoma. An Eastern Cooperative Oncology Group Pilot Study”
`American Journal ofClinical Oncology 11(5):528-534 (Oct. 1988).
`Hamilton and Piccart, “The contribution of molecular markers to the
`prediction of response in the treatment of breast cancer: a review of
`the literature on HER-2, p53 and BCL-2” Annals of Oncology
`11(6):647-663 (Jun. 2000).
`Kaufmann et al., “Exemestane is superior to megestrol acetate after
`tamoxifen failure in postmenopausal women with advanced breast
`cancer: Results of a phase III randomized double-blind trial” Journal
`ofClinical Oncology 18(7):1399-1411 (Apr. 2000).
`Konecny et al., “New drugs in breast cancer therapy: Current position
`and
`future
`perspectives”
`Gynaekologisch-Geburtshih‘liche
`Rundschau (English language abstract only) 37(2):54-61 (Oct.
`1997).
`Kunisue et al., “Anti-HER2 antibody enhances the growth inhibitory
`effect of anti-oestrogen on breast cancer cells expressing both
`oestrogen receptors and HER2” British Journal of Cancer 82(1):46
`51 (Jan. 2000).
`Lohrisch and Piccart, “Breast cancer: new aspects of adjuvant hor
`monal therapy” Annals of Oncology 11(Suppl. 3): 13-25 (2000).
`Mizukami et al., “Effects of tamoxifen, medroxyprogesterone acetate
`and estradiol on tumor growth and oncogene expression in MCF-7
`breast cancer cell line transplanted into nude mice” Anticancer
`Research 11(3): 1333-1338 (May-Jun. 1991).
`Pegram et al., “Effect of erbB-2 (HER-2/neu) overexpression on
`chemotherapeutic drug sensitivity in human breast and ovarian can
`cer cells” Proceedings of the American Association for Cancer
`Research (Abstract No. 152) 34:26 (Mar. 1993).
`Piccart and Kaufmann, “Introduction” European Journal of Cancer
`37(Suppl. 1):S1-S2 (Jan. 2001).
`
`Piccart et al., “HER2: a ‘predictive factor’ ready to use in the daily
`management of breast cancer patients?” European Journal of Cancer
`36(14):1755-1761 (Sep. 2000).
`Piccart, M., “Closing remarks and treatment guidelines” European
`Journal ofCancer 37(Suppl. 1):S30-S33 (Jan. 2001).
`Pietras et al ., “HER-2 tyrosine kinase pathway targets estrogen recep
`tor and promotes hormone-independent growth in human breast can
`cer cells” Oncogene 10(12):2435-2446 (Jun. 15, 1995).
`Pietras et al., “Heregulin promotes growth of human breast cancer
`cells with HER-2 (erb B2) recptors” Proceedings of the American
`Association for Cancer Research (Abstract No. 573) 34:96 (Mar.
`1993).
`Read et al., “Hormonal modulation of HER-2/neu protooncogene
`messenger ribonucleic acid and p185 protein expression in human
`breast cancer cell lines” Cancer Reserach 50(13):3947-3951 (Jul. 1,
`1990).
`Warri et al., “Estrogen suppression of erbB2 expression is associated
`with increased growth rate of ZR-75-1 human breast cancer cells in
`vitro and in nude mice” International Journal of Cancer 49(4):616
`623 (Oct. 21, 1991).
`Witters et al., “Enhanced anti-proliferative activity of the combina
`tion of tamoxifen plus HER-2-neu antibody” Breast Cancer
`Research & Treatment 42(1):1-5 (Jan. 1997).
`“Are adjuvant Herceptin trials using the wrong drugs?” Scrip
`2493:21 (Nov. 26, 1999).
`Arteaga et al., “pl85c'erl’B'2 Signaling Enhances Cisplatin-induced
`Cytotoxicity in Human Breast Carcinoma Cells: Association
`Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced
`DNA Repair” Cancer Research 54(14):3758-3765 (Jul. 15, 1994).
`Bacus et al ., “Differentiation of Cultured Human Breast Cancer Cells
`(AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/
`neu Antigen” Molecular Carcinogenesis 3(6):350-362 (1990).
`Bacus et al., “Tumor-inhibitory Monoclonal Antibodies to the HER
`2/Neu Receptor Induce Differentiation of Human Breast Cancer
`Cells” Cancer Research 52(9):2580-2589 (May 1, 1992).
`Baselga and Mendelsohn, “Receptor Blockade With Monoclonal
`Antibodies As Anti-Cancer Therapy” Pharmac. T her 64:127-154
`(1994).
`Baselga et al., “Anti HER2 Humanized Monoclonal Antibody (MAb)
`Alone and in Combination with Chemotherapy Against Human
`Breast Carcinoma Xenografts” Proceedings of ASCO-1 3th Annual
`Meeting (Abstract #53), Dallas, TX 13:63 (Mar. 1994).
`Baselga et al., “Antitumor activity of paclitaxel in combination with
`anti-growth factor receptor monoclonal antibodies in breast cancer
`xenografts” Proceedings of the American Association for Cancer
`Research (Abstract No. 2262) 35:380 (Mar. 1994).
`Baselga et al., “Antitumor effects of doxorubicin in combination with
`anti-epidermal growth factor receptor monoclonal antibodies” Jour
`nal of the National Cancer Institute 85(16):1327-1333 (Aug. 18,
`1993).
`Baselga et al., “HER2 Overexpression and Paclitaxel Sensitivity in
`Breast Cancer: Therapeutic Implications” Oncology (Supplement
`No.2) 11(3):43-48 (Mar. 1997).
`Baselga et al., “Monoclonal Antibodies Directed Against Growth
`Factor Receptors Enhance the Ef?cacy of Chemotherapeutic
`Agents.” Annals ofOncology (abstract #010) 5(Suppl. 5) (1994).
`Baselga et al., “Phase II Study of Weekly Intravenous Recombinant
`Humanized Anti-p185HER2 Monoclonal Antibody in Patients With
`HER2/neu-Overexpressing Metastatic Breast Cancer” J Clin.
`Oncol. 14(3):737-744 (Mar. 1996).
`Baselga et al., “Recombinant Humanized Anti-HER2 Antibody
`(Herceptin) Enchances the Antitumor Activity of Paclitaxel and
`Doxorubicin against HER2/neu Overexpessing Human Breast Can
`cer Xenografts” Cancer Research 58:2825-2831 (Jul. 1998).
`Bunn et al., “HER2/neu expression and effects of Herceptin alone
`and in combination with cytotoxic agents in lung cancer” Proceed
`ings of theAmerican Association for Cancer Research (Abstract No.
`4571) 41:719 (Mar. 2000).
`Burris et al., “Phase II trial of docetaxel and Herceptin(R) as First- or
`second-line chemotherapy for women with metastatic breast cancer
`whose tumours overexpress HER2” European Journal of Cancer
`(Abstract No. 1293) 35(4):S322 (Sep. 1999).
`
`BIOEPIS EX. 1001
`Page 3
`
`

`

`US 7,892,549 B2
`Page 4
`
`Carmichael et al., “Advanced breast cancer: a phase II trial with
`gemcitabine” Journal of Clinical Oncology 13(11):2731-2736 (Nov.
`1995).
`Carmichael et al., “Advanced breast cancer: investigational role of
`gemcitabine” European Journal of Cancer 33(Suppl. 1):S27-S30
`(Jan. 1997).
`Carter et al., “Humanization of an Anti-p185”ERZ Antibody For
`Human Cancer Therapy” Proc. Natl. Acad Sci. USA 89:4285-4289
`(May 1992).
`Clemons et al., “Review of recent trials of chemotherapy for
`advanced Breast cancer: studies excluding taxanes” European Jour
`nal ofCancer 33(13):2171-2182 (Nov. 1997).
`D’Souza and Taylor-Papadimitriou., “Overexpression of ERBB2 in
`Human Mammary Epithelial Cells Signals Inhibition of Transcrip
`tion of the E-Cadherin Gene.” Proc. Natl. Acad. Sci. USA
`91(15):7202-7206 (Jul. 19, 1994).
`Davidson, N., “Single-agent paclitaxel at ?rst relapse following adju
`vant chemotherapy for breast cancer” Seminars in Oncology 22(6
`Suppl 14):2-6 (Dec. 1995).
`De Santes et al., “RadiolabeledAntibody Targeting of the HER-2/neu
`Oncoprotein” Cancer Research 52: 1916-1923 (1992).
`Di Fiore et al., “erbB-2 Is A Potent Oncogene When Overexpressed
`In NIH/3T3 Cells.” Science 237(481 1): 178-182 (Jul. 10, 1987).
`Drebin et al., “Down-Modulation of an Oncogene Protein Product
`and Reversion of the Transformed Phenotype by Monoclonal Anti
`bodies” Cell 41(3):695-706 (Jul. 1985).
`Drebin et al., “Inhibition of Tumor Growth By a Monoclonal Anti
`body Reactive With an Oncogene-Encoded Tumor Antigen” Proc.
`Natl. Acad. Sci. 83:9129-9133 (1986).
`Drebin et al., “Monoclonal Antibodies Reactive With Distinct
`Domains of the neu Oncogene-Encoded p185 Molecule Exert Syn
`ergistic Anti-Tumor Effects In Vivo” Oncogene 2:273 -277 (1988).
`Drebin et al., “Monoclonal Antibodies Speci?c for the neu Oncogene
`Product Directly Mediate Anti-tumor Effects In Vivo” Oncogene
`2(4):387-394 (1988).
`Fendly, B.M. et al., “Characterization of Murine Monoclonal Anti
`bodies Reactive to Either the Human Epidermal Growth Factor
`Receptor or HER2/neu Gene Product” Cancer Research 50: 1550
`1558(Mar.1,1990).
`Fleiss, J L Statistical Methods for Rates and Proportions, 2nd edition,
`NewYork, NY:Wiley pp. 13-17 (1981).
`Fornier et al., “Trastuzumab in combination with chemotherapy for
`the treatment of metastatic breast cancer” Seminars in Oncology 27(6
`Suppl 11):38-45 (Dec. 2000).
`Gatzemeier et al., “A randomised phase II study of gemcitabine/
`cisplatin alone and with Herceptin in patients with HER2-positive
`non-small cell lung cancer (NSCLC)” (Poster to be presented at the
`2001 ECCO meeting).
`Gemzar (gemcitabine HCL), “Product InformationiPDR” (2000).
`Green et al., “Preclinical Evaluation of WR-151327: An Orally
`Active Chemotherapy Protector” Cancer Research 54(3):738-741
`(Feb. 1, 1994).
`Guy et al., “Expression of the neu Protooncogene in the Mammary
`Epithelium of Transgenic Mice Induces Metastatic Disease.” Proc.
`Natl. Acad. Sci. USA 89(22):10578-10582 (Nov. 15, 1992).
`Hancock et al., “A Monoclonal Antibody Against the c-erbB-2 Pro
`tein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum
`Against Human Breast and Ovarian Tumor Cell Lines” Cancer
`Research 51:4575-4580 (Sep. 1, 1991).
`Hansen, H., “Gemcitabineia review”Annals of Oncology (Abstract
`#05 8 from the 9th NCI-EORTC Symposium on New Drugs in Cancer
`Therapy held in Amsterdam on Mar. 12-15, 1996) 7(Suppl. 1):29
`(1996).
`Harwerth et al., “Monoclonal Antibodies Against the Extracellular
`Domain of the erbB-2 Receptor Function as Partial Ligand Agonists”
`Journal of Biological Chemistry 267(21):15160-15167 (Jul. 25,
`1992).
`“Herceptin (Trastuzumab)” Product Information (2000).
`Hudziak et al., “Increased Expression of the Putative Growth Factor
`Receptor p185HER2 Causes Transformation and Tumorigenesis of
`NIH 3T3 Cells”Proc. Natl. Acad Sci. USA 84(20):7159-7163 (Oct.
`1987).
`
`Hudziak et al., “p185HER2 Monoclonal Antibody Has Antiprolifera
`tive Effects In Vitro and Sensitizes Human Breast Tumor Cells to
`Tumor Necrosis Factor” Molecular & Cellular Biology 9(3): 1 165
`1172 (Mar. 1989).
`Hynes and Stern., “The Biology of erbB-2/neu/ HER-2 and Its Role in
`Cancer.” Biochimica et Biophysica Acta 1198(2-3):165-184 (Dec.
`30, 1994).
`Ilgen et al., “Characterization of anti-HEIU2 antibodies which inhibit
`the growth of breast tumor cells in vitro” Proceedings of the Ameri
`can Association for Cancer Research (abstract #3209) 37:470 (Mar.
`1996).
`Kasprzyk et al., “Therapy of an Animal Model of Human Gastric
`Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibod
`ies” Cancer Research 52(10):2771-2776 (May 15, 1992).
`Konecny et al., “Therapeutic advantage of chemotherapy drugs in
`combination with Herceptin against human breast cancer cells with
`HER-2/N EU overexpression” Breast CancerRes Treat (Abstract No.
`467) 571114 (1999).
`Kotts et al., “Differential Growth Inhibition of Human Carcinoma
`Cells Exposed to Monoclonal Antibodies Directed against the
`Extracellular Domain of the HER2/ERBB2 Protooncogene” In J/ltro
`(Abstract #176) 26(3):59A (1990).
`Kumar et al., “Regulation of Phosphorylation of the c-erbB-2/HER2
`Gene Product by a Monoclonal Antibody and Serum Growth Fac
`tor(s) in Human Mammary Carcinoma Cells” Molecular & Cellular
`Biology 11(2):979-986 (Feb. 1991).
`Lewis et al., “Differential Responses of Human Tumor Cell Lines to
`Anti-p185HER2 Monoclonal Antibodies.” Cancer Immunol.
`Immunother 37:255-263 (1993).
`Lewis et al., “Growth Regulation of Human Breast and Ovarian
`Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2
`as a Critical Component in Mediating Heregulin Responsiveness”
`Cancer Research 56:1457-1465 (Mar. 15, 1996).
`Llombart et al., “Biweekly gemcitabine and paclitaxel in advanced
`breast cancer. Phase II trial and predictive value of HER2 extracel
`lular domain (ECD)” European Journal of Cancer (Abstract No.
`390) 36(Suppl 5):S121-S122 (Sep. 2000).
`Maier et al., “Requirements for the Internalization of a Murine
`Monoclonal Antibody Directed against the HER-2/neu Gene Product
`c-erbB-2” Cancer Research 51(19):5361-5369 (Oct. 1, 1991).
`Masui et al., “Growth Inhibition of Human Tumor Cells in Athymic
`Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Anti
`bodies” Cancer Research 44(3): 1002-1007 (Mar. 1984).
`Masuko et al., “A murine Monoclonal Antibody That Recognizes an
`Extracellular Domain of the Human c-erbB-2 Protooncogene Prod
`uct” Jpn J Cancer Res. 80:10-14 (Jan. 1989).
`McCann et al., “c -erbB-2 Oncoprotein Expression in Primary Human
`Tumors” Cancer 65(1):88-92 (Jan. 1, 1990).
`McKenzie et al., “Generation and Characterization of Monoclonal
`Antibodies Speci?c for the Human neu Oncogene Product, p185”
`Oncogene 4:543-548 (1989).
`Mendelsohn et al., “Receptor Blockade and Chemotherapy: A New
`Approach to Combination Cancer therapy. ” Annals of Oncology
`(abstract #040) 7(Suppl. 1):22 (1996).
`Miller et al., “Gemcitabine, paclitaxel, and trastuzumab in metastatic
`breast cancer” Oncology 15(2 Supp 3):38-40 (Feb. 2001).
`Miller et al., “Phase II study of gemcitabine, paclitaxel and
`trastuzumab in metastatic breast cancer; a Hoosier Oncology Group
`trial” (Abstract #437. Presented at the 2002 SABCS meeting.)
`(2002).
`Mosconi et al., “Combination therapy with gemcitabine in non-small
`cell lung cancer” European Journal ofCancer 33(Suppl. 1):S 14-S 17
`(Jan. 1997).
`Myers et al., “Biological Effects of Monoclonal Antireceptor Anti
`bodies Reactive with neu Oncogene Product, p185neu” Methods in
`Enzymology 198:277-290 (1991).
`Nagourney et al., “Trastuzumab (Herceptin) enhancement of
`cytotoxic drug activity in human tumor primary cultures” Breast
`Cancer Res Treat (Abstract No. 475) 57: 1 16 (1999).
`Nelson and Fry, “Inhibition of ERBB family receptors by C1-1033
`enhances the cytotoxicity of gemcitabine via modulation of AKT and
`map kinases” Proceedings of the American Association for Cancer
`Research (Abstract No. 1533) 41:241 (Mar. 2000).
`
`BIOEPIS EX. 1001
`Page 4
`
`

`

`US 7,892,549 B2
`Page 5
`
`Norton, L., “Evolving Concepts in the Systemic Drug Therapy of
`Breast Cancer” Seminars in Oncology 24(4 Suppl 10): S10-3-S 10-10
`(Aug. 1997).
`Pegram et al., “Inhibitory effects of combinations of HER-2/neu
`antibody and chemotherapeutic agents used for treatment of human
`breast cancers” Oncogene 18:2241-2251 (1999).
`Pietras et al., “Antibody to HER-2/neu Receptor Blocks DNA Repair
`After Cisplatin in Human Breast and Ovarian Cancer Cells”
`Oncogene 9: 1829-1838 (1994).
`Raefsky et al., “Phase II Trial of Docetaxel and Herceptin as First- or
`Second-Line Chemotherapy for Women with Metastatic Breast Can
`cer Whose Tumors Overexpress HER2” Proceedings of ASCO
`(Abstract #523) 18:137a (1999).
`Ravdin and Chamness, “The c-erbB-2 proto-oncogene as a prognos
`tic and predictive marker in breast cancer: a paradigm for the devel
`opment of other macromolecular markersia review” Gene
`159(1):19-27 (Jun. 14, 1995).
`Rodeck et al., “Interactions between growth factor receptors and
`corresponding monoclonal antibodies in human tumors” J Cellular
`Biochem. 35(4):315-320 (1987).
`Safran et al., “Herceptin and gemcitabine for metastatic pancreatic
`cancers that overexpress HER-2/neu” Proc. Am. Soc. Clin. Oncol.
`(Abstract No. 5 17) 20: 130A (2001).
`Sarup et al., “Characterization of an Anti-P185HER2 Monoclonal
`Antibody that Stimulates Receptor Function and Inhibits Tumor Cell
`Growth” Growth Regulation 1:72-82 (1991).
`Schlom, J ., “Monoclonal Antibodies: They’re More and Less Than
`You Think” Molecular Foundations of Oncology, Broder, S. ed.,
`Baltimore, MD:Williams & Wilkins, Chapter 6, pp. 95-134 (1991).
`Scott et al., “p185HER2 Signal Transduction in Breast Cancer Cells”
`Journal of Biological Chemistry 266(22): 14300-14305 (Aug. 5,
`1991).
`Seidman et al., “Memorial Sloan-Kettering Cancer Center experi
`ence with paclitaxel in the treatment of breast cancer” Seminars in
`Oncology 22(5 Suppl 12):108-116 (Oct. 1995).
`Seifert et al., “Dexrazoxane in the prevention of doxorubicin-induced
`cardiotoxicity” Annals of Pharmacotherapy 28(9): 1063-1072 (Sep.
`1994).
`Shawver et al., “Ligand-Like Effects Induced by Anti-c-erbB-2 Anti
`bodies Do Not Correlate with and Are Not Required for Growth
`Inhibition of Human Carcinoma Cells” Cancer Research
`54(5):1367-1373 (Mar. 1, 1994).
`Shepard et al., “Monoclonal Antibody Therapy of Human Cancer:
`Taking the HER2 Protooncogene to the Clinic” J Clin. Immunol.
`11(3): 1 17-127 (1991).
`Singal and Iliskovic, “Doxorubicin-induced cardiomyopathy” New
`EnglandJ ofMedicine 339(13):900-905 (Sep. 24, 1998).
`Singal et al., “Combination therapy with probucol prevents
`adriamycin-induced cardiomyopathy” Journal of Molecular & Cel
`lular Cardiology 27(4): 1055-1063 (Apr. 1995).
`Slamon et al., “Human Breast Cancer: Correlation of Relapse and
`Survival with Ampli?cation of the HER-2/neu Oncogene” Science
`235:177-182 (Jan. 9, 1987).
`Slamon et al., “Studies of the HER-2/neu Proto-Oncogene in Human
`Breast and Ovarian Cancer” Science 244:707-712 (May 12, 1989).
`Sliwkowski et al., “A humanized monoclonal antibody for the treat
`ment of HER2 overexpressing breast cancer” Proceedings of the
`American Association for Cancer Research (abstract only) 37:625
`626 (Mar. 1996).
`Sliwkowski et al., “Coexpression of erbB2 and erbB3 Proteins
`Reconstitutes a High Af?nity Receptor for Heregulin” Journal of
`Biological Chemistry 269(20): 14661-14665 (May 20, 1994).
`Stancovski et al., “Mechanistic Aspects of the Opposing Effects of
`Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth”
`Proc. Natl. Acad. Sci. USA 88(19):8691-8695 (Oct. 1, 1991).
`Tagliabue et al., “Selection of Monoclonal Antibodies Which Induce
`Internalization and Phosphorylation of p185HER2 and Growth Inhi
`bition of Cells With HER2/N EU Gene Ampli?cation” International
`Journal ofCancer 47(6):933-937 (Apr. 1, 1991).
`Tsai et al., “Cytotoxic effects of gemcitabine-containing regimens
`against human non-small cell lung cancer cell lines which express
`different levels of p185””’” CancerResearch 56(4):794-801 (Feb. 15,
`1996).
`
`van Moorsel et al., “Combination chemotherapy studies with
`gemcitabine” Seminars in Oncology 24(2 Suppl. 7):S7-17-S7-23
`(Apr. 1997).
`Vitetta and Uhr, “Monoclonal Antibodies as Agonists: An Expanded
`Role for Their Use in Cancer Therapy” Cancer Research
`54(20):5301-5309 (Oct. 15, 1994).
`Xu et al., “Antibody-Induced Growth Inhibition is Mediated Through
`Immunochemically and Functionally Distinct Epitopes on the
`Extracellular Domain of the c-erbB-2 (HER-2/neu) Gene Product
`p185” InternationalJournal ofCancer 53(3):401-408 (Feb. 1, 1993).
`Zhang et al., “Shared antigenic epitopes and pathobiological func
`tions of anti-p185h”2/”€” monoclonal antibodies” Experimental and
`Molecular Pathology 67:15-25 (1999).
`Zinner et al., “Cisplation and gemcitabine combined with Herceptin
`in patients (Pts) with HER2 overexpressing, untreated, advanced,
`non-small-cell lung cancer (NSCLC); a phase II trial” Proc. Am. Clin.
`Oncol. Abstract No. 1307) 20:328A (2001).
`Buzdar et al., “Anastrozole, a potent and selective aromatase inhibi
`tor, versus megestrol acetate in postmenopausal women with
`advanced breast cancer: results of overview analysis of two phase III
`trials” Journal ofClinical Oncology 14(7):2000-2011 (Jul. 1996).
`Buzdar et al., “Fadrozole HCL (CGS-16949A) versus megestrol
`acetate treatment of postmenopausal patients with metastatic breast
`carcinoma: results of two randomized double blind controlled
`multiinstitutional trials” Cancer 77(12):2503-2513 (Jun. 15, 1996).
`Dickman, S., “Antibodies stage a comeback in cancer treatment”
`Science 280(5367):1196-1197 (May 22, 1998).
`Grant et al., “Comparison of antiangiogenic activities using
`paclitaxel (taxol) and docetaxel (taxotere)” International Journal of
`Cancer 104(1):121-129 (Mar. 10, 2003).
`Kaye et al., “Phase II trials of docetaxel (Taxotere) in advanced
`ovarian cancerian updated overview” European Journal of Cancer
`33(13):2167-2170 (Nov. 1997).
`Klijn et al., “Clinical breast cancer, new developments in selection
`and endocrine treatment of patients” Journal of Steroid Biochemistry
`& Molecular Biology 43(1-3):211-221 (Sep. 1992).
`Merlin et al., “In vitro comparative evaluation of trastuzumab
`(Herceptin) combined with paclitaxel (Taxol) or docetaxel (Taxotere)
`in HER2-expressing human breast cancer cell lines” Annals of
`Oncology 13(11):1743-1748 (Nov. 2002).
`Nallani et al., “Differences in the induction of cytochrome P450 3A4
`by taxane anticancer drugs, docetaxel and paclitaxel, assessed
`employing primary human hepatocytes” Cancer Chemotherapy &
`Pharmacology 54:219-229 (Sep. 2004).
`Santen and Harvey, “Use of aromatase inhibitors in breast carci
`noma” Endocrine-Related Cancer 6(1):75-92 (Mar. 1999).
`Untch et al., “Comparison of paclitaxel and docetaxel (Taxotere) in
`gynecologic and breast cancer cell lines with the ATP-cell viability
`assay”Anti-Cancer Drugs 5(1):24-30 (Feb. 1994).
`Agus et al., “Clinical Activity in a Phase I Trial of HER-2-Targeted
`rhuMAb 2C4 (pertuzumab) in Patients with Advanced Solid Malig
`nancies (AST)”Proceedings of theAmericanAssociation for Cancer
`Research (Abstract No. 771) 22:192 (2003).
`Agus et al., “Clinical Activity in a Phase I Trial of HER2-Targeted
`rhuMAb 2C4 (pertuzumab) in Patients with Advanced Solid Malig
`nancies” (Slides presented at the 2003 ASCO Annual Meeting) pp.
`1-32 (2003).
`Gordon et al., “Clinical activity of pertuzumab (rhuMab 2C4) in
`advanced, refractory or recurrent ovarian cancer (OC), and the role of
`HER2 activation status” Journal of Clinical Oncology (Abstract
`#5051 from the 41st Annual Meeting ofASCO) 23(16S):467s (Jun. 1,
`2005).
`Gordon et al., “Clinical activity of pertuzumab (rhuMab 2C4) in
`advanced, refractory or recurrent ovarian cancer and the role of
`HER2 activation status” (Poster #5051 from the 41st Annual Meeting
`of the American Society of Clinical Oncology (ASCO)) (May 15,
`2005).
`Herzig and Herzig, “Medical Oncology” (website link: http://www.
`qualitysurgical.org/Chapter%2033 .htm) pp. 1-11 (2006).
`Marty et a1 ., “Randomized Phase II Trial of the Ef?cacy and Saftey of
`Trastuzumab Combined with Docetaxel in Patients with Human Epi
`dermal Growth Factor Receptor 2-Po sitive Metastatic Breast Cancer
`
`BIOEPIS EX. 1001
`Page 5
`
`

`

`US 7,892,549 B2
`Page 6
`
`Administered As First-Line Treatment” Journal of Clinical Oncol
`ogy 23(19):4265-4274 (Jul. 1,2005).
`BrodowicZ et al., “Single-agent gemcitabine as second- and third-line
`treatment in metastatic breast cancer” The Breast 9:338-342 (2000).
`Brufsky et al., “Phase II study of gemcitabine (Gem) and trastuZumab
`(T) combination therapy in ?rst line metastatic breast cancer (MBC)
`patients (pts) with HER2 overexpression” Jou